Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
46
CLDX Quote, Financials, Valuation and Earnings
Last price:
$29.61
Seasonality move
:
15.7%
Day range:
$27.68 - $29.71
52-week range:
$14.40 - $29.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
755.79x
P/B ratio:
3.29x
Volume:
741.7K
Avg. volume:
814.6K
1-year change:
11.36%
Market cap:
$2B
Revenue:
$7M
EPS (TTM):
-$3.38
Analysts' Opinion
-
Consensus RatingCelldex Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $53.14, Celldex Therapeutics, Inc. has an estimated upside of 79.54% from its current price of $29.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 100% downside risk from its current price of $29.60.
Fair Value
-
According to the consensus of 13 analysts, Celldex Therapeutics, Inc. has 79.54% upside to fair value with a price target of $53.14 per share.
CLDX vs. S&P 500
-
Over the past 5 trading days, Celldex Therapeutics, Inc. has overperformed the S&P 500 by 10.36% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Celldex Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Celldex Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Celldex Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Celldex Therapeutics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Celldex Therapeutics, Inc. reported earnings per share of -$1.01.
Enterprise value:
1.4B
EV / Invested capital:
2.32x
Price / LTM sales:
755.79x
EV / EBIT:
--
EV / Revenue:
535.50x
PEG ratio (5yr expected):
-0.28x
EV / Free cash flow:
-7.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$783K
Return On Assets:
-30.38%
Net Income Margin (TTM):
-8635.85%
Return On Equity:
-32.17%
Return On Invested Capital:
-32.02%
Operating Margin:
-8747.53%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.4M | $10M | $2.6M | $3.2M | -- | |
| Gross Profit | $1.4M | $6.9M | -$783K | $2.4M | -$824K | |
| Operating Income | -$134.8M | -$174.2M | -$256.2M | -$52.1M | -$73.6M | |
| EBITDA | -$131.9M | -$171.1M | -$252.9M | -$51.3M | -$72.8M | |
| Diluted EPS | -$2.64 | -$2.57 | -$3.38 | -$0.64 | -$1.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $426.6M | $334.6M | $245.9M | $778.8M | $604.3M | |
| Total Assets | $460.2M | $369.2M | $280.3M | $823.2M | $648.4M | |
| Current Liabilities | $14.2M | $16.3M | $27.8M | $32.1M | $46.5M | |
| Total Liabilities | $23.5M | $23.8M | $33.5M | $37.3M | $50.1M | |
| Total Equity | $436.7M | $345.4M | $246.7M | $785.9M | $598.4M | |
| Total Debt | $1.7M | $2.2M | $1.3M | $1.7M | $1.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$96.5M | -$157.8M | -$179.5M | -$55.3M | -$48.6M | |
| Cash From Investing | $96.6M | -$485.3M | $177.7M | $47.8M | $60.8M | |
| Cash From Financing | $2.5M | $658.4M | $1.4M | $1.2M | $774K | |
| Free Cash Flow | -$97.9M | -$159.7M | -$181.7M | -$55.9M | -$49.1M | |
CLDX
Sector
Market Cap
$2B
$28.4M
Price % of 52-Week High
99.63%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.09%
-1.32%
1-Year Price Total Return
11.36%
-22.19%
Beta (5-Year)
1.133
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$27.08
200-day SMA
Buy
Level
$22.29
Bollinger Bands (100)
Buy
Level
22.6 - 26.58
Chaikin Money Flow
Sell
Level
-243.4M
20-day SMA
Buy
Level
$25.54
Relative Strength Index (RSI14)
Buy
Level
68.57
ADX Line
Buy
Level
13.24
Williams %R
Sell
Level
-1.7628
50-day SMA
Buy
Level
$26.02
MACD (12, 26)
Buy
Level
0.66
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Sell
Level
-13.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.7187)
Buy
CA Score
(Annual)
Level (0.1374)
Buy
Beneish M-Score
(Annual)
Level (-3.1586)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (3.5989)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Stock Forecast FAQ
In the current month, CLDX has received 11 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CLDX average analyst price target in the past 3 months is $53.14.
-
Where Will Celldex Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Celldex Therapeutics, Inc. share price will rise to $53.14 per share over the next 12 months.
-
What Do Analysts Say About Celldex Therapeutics, Inc.?
Analysts are divided on their view about Celldex Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Celldex Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Celldex Therapeutics, Inc.'s Price Target?
The price target for Celldex Therapeutics, Inc. over the next 1-year time period is forecast to be $53.14 according to 13 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CLDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Celldex Therapeutics, Inc. is a Buy. 11 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CLDX?
You can purchase shares of Celldex Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Celldex Therapeutics, Inc. shares.
-
What Is The Celldex Therapeutics, Inc. Share Price Today?
Celldex Therapeutics, Inc. was last trading at $29.61 per share. This represents the most recent stock quote for Celldex Therapeutics, Inc.. Yesterday, Celldex Therapeutics, Inc. closed at $29.60 per share.
-
How To Buy Celldex Therapeutics, Inc. Stock Online?
In order to purchase Celldex Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CLDX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLDX
Sector
P/E ratio
--
23.66x
PEG ratio
-0.28x
-0.01x
P/B ratio
3.29x
1.84x
Price / LTM sales
755.79x
1.60x
Growth Metrics
CLDX
Sector
Revenue growth
-100%
4.85%
Earnings growth
-58.86%
11.15%
Revenue (5-year growth)
14.46%
6.45%
Earnings forecast
-$0.90
-$0.20
Profitability
CLDX
Sector
Profitability FY 2024
$3.8M
$3.6M
Return on invested capital
-32.02%
-30.98%
Return on assets
-30.38%
-27.62%
Return on equity
-32.17%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
9
Balance Sheet
CLDX
Sector
Total cash
$577.2M
$27.2M
Short term investments
$696.9M
$25.7M
Total assets
$792.3M
$79.9M
Long term debt
$1.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
